Legend Bio Plans to Raise $250 Million in Public Offering of Shares
publication date: Jul 26, 2022
Legend Biotech, a New Jersey-Nanjing cell therapy company, announced plans to raise $250 million by selling American Depositary Shares in an underwritten public offering. In February, Legend was approved to launch its BCMA CAR-T therapy, Carvykti, as a fitth-line therapy for multiple myeloma in the US, and EU approval followed in May. At the recent ASCO convention, Legend revealed the CAR-T had not reached a median progression of disease or death after more than two years in MM patients. Legend is conducting tests of Carvykti as a second-line therapy for MM. More details....
Stock Symbol: (NSDQ: LEGN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.